EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Malignant Rhabdoid Tumors of the Liver Are Associated With Inferior Outcomes Compared to Other Extracranial Rhabdoid Tumors

Sebastian Bühner iD, Katharina Gastberger, Stefanie Tüchert-Knoll iD, Victoria E Fincke iD, Pascal D Johann, Patrick Melchior, Margarita Teleshova, Denis Kachanov, Alexey Shcherbakov iD, Irene Schmid, Kleoniki Roka, Reiner Siebert und 5 weitere

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.32062 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Sebastian Bühner und 16 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics and Adolescent Medicine, Swabian Children's Cancer Center, University Hospital Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Rhabdoid Tumor, Liver Neoplasms, Kidney Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe, Deutsche Kinderkrebsstiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Extracranial malignant rhabdoid tumors (eMRT) are rare, highly aggressive pediatric neoplasms. While the liver is a relatively common anatomic site of presentation, the clinical course of patients with hepatic eMRT (eMRT‐L) is not well described.

Methods

We retrospectively analyzed 30 children affected by eMRT‐L treated on a consensus regimen provided by the European Rhabdoid Registry (EU‐RHAB). Clinical characteristics, radiology features according to the Pre‐Treatment Extent of Tumor (PRETEXT) system, treatment details, and outcome were assessed. We employed patients with rhabdoid tumors of the kidney (RTK; n = 30) and other eMRT ( n = 60) as controls.

Results

Median age at diagnosis was 8 months (range: 0–53 months), 16 of 30 patients (55%) presented with metastatic disease. R0 resection was achieved in seven patients (23%). Most tumors showed PRETEXT Stage ≥ 3 (66%) and frequently exhibited PRETEXT annotation factors. One‐year overall and event‐free survivals were both 17% (95% confidence interval: 7.5–37). Compared to RTK and other eMRT, patients with eMRT‐L had significantly inferior outcomes (hazard ratios 2.47 and 4.39, respectively). Complete resection and absence of metastases were associated with improved survival. Consolidation therapies (i.e., radiotherapy or high‐dose chemotherapy) were only rarely used.

Conclusions

EMRT‐L represents a distinct high‐risk subgroup within the eMRT spectrum, characterized by inferior survival despite standardized multimodal therapy. Current treatment approaches demonstrate limited efficacy. Our results highlight the urgent need for prospective, collaborative studies to refine risk stratification and to evaluate novel treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rhabdoid TumorLiver NeoplasmsKidney NeoplasmsHumansFemaleMaleInfantChild, PreschoolRetrospective StudiesSurvival RateInfant, NewbornPrognosisFollow-Up StudiesCombined Modality Therapy

Stichwörter der Autor:innen

EU‐RHAB registryPRETEXTSMARCB1livermalignant rhabdoid tumor

Autor:innen und Institutionen

  • Pediatrics and Adolescent Medicine, Swabian Children's Cancer Center, University Hospital Augsburg, Augsburg, Germany.
  • Bavarian Cancer Research Center (BZKF), Augsburg, Germany.
  • Department of Diagnostic and Interventional Radiology, University Hospital Augsburg, Augsburg, Germany.
  • Department of Radiation Oncology, Saarland University Hospital, Homburg, Germany.
  • Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Department of Pediatric Oncology and Hematology, Dr. Von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.

ORCID-Profile: Sebastian Bühner, Stefanie Tüchert-Knoll, Victoria E Fincke, Alexey Shcherbakov, Christian Vokuhl, Michael C Frühwald

Förderung

  • Deutsche Krebshilfe
  • Deutsche Kinderkrebsstiftung

Zitieren

APA

Bühner, S., Gastberger, K., Tüchert-Knoll, S., Fincke, V. E., Johann, P. D., Melchior, P., Teleshova, M., Kachanov, D., Shcherbakov, A., Schmid, I., Roka, K., Siebert, R., Vokuhl, C., Gerss, J., Fuchs, J., Furtwängler, R., & Frühwald, M. C. (2025). Malignant Rhabdoid Tumors of the Liver Are Associated With Inferior Outcomes Compared to Other Extracranial Rhabdoid Tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32062

Vancouver

Bühner S, Gastberger K, Tüchert-Knoll S, Fincke VE, Johann PD, Melchior P, et al. Malignant Rhabdoid Tumors of the Liver Are Associated With Inferior Outcomes Compared to Other Extracranial Rhabdoid Tumors. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32062

BibTeX
@article{Bhner2025,
  author = {Bühner, Sebastian and Gastberger, Katharina and Tüchert-Knoll, Stefanie and Fincke, Victoria E and Johann, Pascal D and Melchior, Patrick and Teleshova, Margarita and Kachanov, Denis and Shcherbakov, Alexey and Schmid, Irene and Roka, Kleoniki and Siebert, Reiner and Vokuhl, Christian and Gerss, Joachim and Fuchs, Jörg and Furtwängler, Rhoikos and Frühwald, Michael C},
  title = {Malignant Rhabdoid Tumors of the Liver Are Associated With Inferior Outcomes Compared to Other Extracranial Rhabdoid Tumors},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.32062}
}
Kostenlos starten →